|
|
|
|
|
|
|
|
|
03.06.25 - 22:06
|
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire EN)
|
|
|
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well tolerated, particularly when compared to standard of care biologics or JAKs....
|
|
|
27.05.25 - 22:18
|
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire EN)
|
|
|
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.03.25 - 14:18
|
Anaptys Announces Stock Repurchase Plan (GlobeNewswire EN)
|
|
|
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share....
|
|
|
04.03.25 - 13:18
|
Where AnaptysBio Stands With Analysts (Benzinga)
|
|
|
Latest Ratings for ANAB
DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy May 2021UBSInitiates Coverage OnNeutral
View More Analyst Ratings for ANAB
View the Latest Analyst Ratings
read more...
|
|
|
|
|
27.02.25 - 22:18
|
Anaptys Announces Participation in March Investor Conferences (GlobeNewswire EN)
|
|
|
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:...
|
|
|
|
|
|
|
|
|
12.02.25 - 14:12
|
XFRA : AN6: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
ANAPTYSBIO INC. DL-,001 AN6 US0327241065
AB/FROM ONWARDS 12.02.2025 14:05 CET...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
